OpenURL Connection Search

Select item for more details and to access through your institution.

Detailed assessment of NOD2/CARD15 exonic variation in inflammatory bowel disease in Scotland: implications for disease pathogenesis.
Published in:
Genes & Immunity, 2008, v. 9, n. 6, p. 556, doi. 10.1038/gene.2008.44
By:
- Russell, R. K.;
- Drummond, H. E.;
- Wilson, D. C.;
- Anderson, N. H.;
- Arnott, I. D. R.;
- Van Limbergen, J. E.;
- Satsangi, J.;
- Nimmo, E. R.
Publication type:
Article
NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?
Published in:
Genes & Immunity, 2004, v. 5, n. 5, p. 417, doi. 10.1038/sj.gene.6364111
By:
- Arnott, I. D. R.;
- Nimmo, E. R.;
- Drummond, H. E.;
- Fennell, J.;
- Smith, B. R. K.;
- MacKinlay, E.;
- Morecroft, J.;
- Anderson, N.;
- Kelleher, D.;
- O'Sullivan, M.;
- McManus, R.;
- Satsangi, J.
Publication type:
Article
Endoscopic ultrasonography in the diagnosis and management of suspected upper gastrointestinal submucosal tumours.
Published in:
British Journal of Surgery, 2002, v. 89, n. 2, p. 231, doi. 10.1046/j.0007-1323.2001.02002.x
By:
- Shen, E. F;
- Arnott, I. D. R;
- Plevris, J;
- Penman, I. D
Publication type:
Article
Anti- Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.
Published in:
Clinical & Experimental Immunology, 2004, v. 135, n. 3, p. 490, doi. 10.1111/j.1365-2249.2003.02392.x
By:
- Walker, L. J.;
- Aldhous, M. C.;
- Drummond, H. E.;
- Smith, B. R. K.;
- Nimmo, E. R.;
- Arnott, I. D. R.;
- Satsangi, J.
Publication type:
Article
Diverticular disease in Scotland: 2000-2010.
Published in:
Colorectal Disease, 2015, v. 17, n. 4, p. 329, doi. 10.1111/codi.12811
By:
- Paterson, H. M.;
- Arnott, I. D.;
- Nicholls, R. J.;
- Clark, D.;
- Bauer, J.;
- Bridger, P. C.;
- Crowe, A. M.;
- Knight, A. D.;
- Hodgkins, P.;
- Solomon, D.;
- Dunlop, M. G.
Publication type:
Article
Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease.
Published in:
2009
By:
- Russell RK;
- Ip B;
- Aldhous MC;
- MacDougall M;
- Drummond HE;
- Arnott ID;
- Gillett PM;
- McGrogan P;
- Weaver LT;
- Bisset WM;
- Mahdi G;
- Wilson DC;
- Satsangi J;
- Russell, R K;
- Ip, B;
- Aldhous, M C;
- MacDougall, M;
- Drummond, H E;
- Arnott, I D R;
- Gillett, P M
Publication type:
journal article
Hepatobiliary cystadenoma with mesenchymal stroma may mimic biliary smooth muscle neoplasms.
Published in:
Histopathology, 2001, v. 39, n. 4, p. 434, doi. 10.1046/j.1365-2559.2001.1262c.x
By:
- Wong, N A C S;
- Arnott, I D R;
- Pope, I;
- Palmer, K R;
- Garden, O J;
- Thomas, J St J;
- Piris, J
Publication type:
Article
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2007, v. 26, n. 3, p. 411, doi. 10.1111/j.1365-2036.2007.03383.x
By:
- LEES, C. W.;
- HEYS, D.;
- HO, G. T.;
- NOBLE, C. L.;
- SHAND, A. G.;
- MOWAT, C.;
- BOULTON‐JONES, R.;
- WILLIAMS, A.;
- CHURCH, N.;
- SATSANGI, J.;
- ARNOTT, I. D. R.
Publication type:
Article
The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort.
Published in:
Alimentary Pharmacology & Therapeutics, 2006, v. 24, n. 2, p. 319, doi. 10.1111/j.1365-2036.2006.02974.x
By:
- HO, G.‐T.;
- CHIAM, P.;
- DRUMMOND, H.;
- LOANE, J.;
- ARNOTT, I. D. R.;
- SATSANGI, J.
Publication type:
Article
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2003, v. 17, n. 12, p. 1451, doi. 10.1046/j.1365-2036.2003.01574.x
By:
- Arnott, I. D. R.;
- McNeill, G.;
- Satsangi, J.
Publication type:
Article
Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?
Published in:
Alimentary Pharmacology & Therapeutics, 2002, v. 16, n. 5, p. 857, doi. 10.1046/j.1365-2036.2002.01242.x
By:
- Arnott, I. D. R.;
- Watts, D.;
- Ghosh, S.
Publication type:
Article
Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience.
Published in:
Alimentary Pharmacology & Therapeutics, 2001, v. 15, n. 10, p. 1639, doi. 10.1046/j.1365-2036.2001.01092.x
By:
- Arnott, I. D. R.;
- McDonald, D.;
- Williams, A.;
- Ghosh, S.
Publication type:
Article
Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data.
Published in:
Alimentary Pharmacology & Therapeutics, 2016, v. 43, n. 11, p. 1132, doi. 10.1111/apt.13614
By:
- Lynch, R. W.;
- Churchhouse, A. M. D.;
- Protheroe, A.;
- Arnott, I. D. R.
Publication type:
Article
Systematic review: the use of thiopurines or anti- TNF in post-operative Crohn's disease maintenance - progress and prospects.
Published in:
Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 11, p. 1253, doi. 10.1111/apt.12743
By:
- Jones, G. R.;
- Kennedy, N. A.;
- Lees, C. W.;
- Arnott, I. D.;
- Satsangi, J.
Publication type:
Article
Letter: acute severe ulcerative colitis - should all patients be treated equally? Authors' reply.
Published in:
Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 1, p. 114, doi. 10.1111/apt.12545
By:
- Lynch, R. W.;
- Arnott, I. D. R.
Publication type:
Article
A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.
Published in:
Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 10, p. 1255, doi. 10.1111/apt.12511
By:
- Kennedy, N. A.;
- Rhatigan, E.;
- Arnott, I. D. R.;
- Noble, C. L.;
- Shand, A. G.;
- Satsangi, J.;
- Lees, C. W.
Publication type:
Article
Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit.
Published in:
Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 8, p. 935, doi. 10.1111/apt.12473
By:
- Lynch, R. W.;
- Lowe, D.;
- Protheroe, A.;
- Driscoll, R.;
- Rhodes, J. M.;
- Arnott, I. D. R.
Publication type:
Article
Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004–2008).
Published in:
Alimentary Pharmacology & Therapeutics, 2009, v. 29, n. 5, p. 527, doi. 10.1111/j.1365-2036.2008.03919.x
By:
- HO, G. T.;
- MOWAT, A.;
- POTTS, L.;
- CAHILL, A.;
- MOWAT, C.;
- LEES, C. W.;
- HARE, N. C.;
- WILSON, J. A.;
- BOULTON‐JONES, R.;
- PRIEST, M.;
- WATTS, D. A.;
- SHAND, A. G.;
- ARNOTT, I. D.;
- RUSSELL, R. K.;
- WILSON, D. C.;
- MORRIS, A. J.;
- SATSANGI, J.
Publication type:
Article
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.
Published in:
Alimentary Pharmacology & Therapeutics, 2009, v. 29, n. 3, p. 286, doi. 10.1111/j.1365-2036.2008.03882.x
By:
- LEES, C. W.;
- ALI, A. I.;
- THOMPSON, A. I.;
- HO, G.‐T.;
- FORSYTHE, R. O.;
- MARQUEZ, L.;
- COCHRANE, C. J.;
- AITKEN, S.;
- FENNELL, J.;
- ROGERS, P.;
- SHAND, A. G.;
- PENMAN, I. D.;
- PALMER, K. R.;
- WILSON, D. C.;
- ARNOTT, I. D. R.;
- SATSANGI, J.
Publication type:
Article
The use of adalimumab in the management of refractory Crohn’s disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2008, v. 27, n. 4, p. 308, doi. 10.1111/j.1365-2036.2007.03583.x
By:
- HO, G.‐T.;
- SMITH, L.;
- AITKEN, S.;
- LEE, H. M.;
- TING, T.;
- FENNELL, J.;
- LEES, C. W.;
- PALMER, K. R.;
- PENMAN, I. D.;
- SHAND, A. G.;
- ARNOTT, I. D.;
- SATSANGI, J.
Publication type:
Article
Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2008, v. 27, n. 3, p. 220, doi. 10.1111/j.1365-2036.2007.03570.x
By:
- LEES, C. W.;
- MAAN, A. K.;
- HANSOTI, B.;
- SATSANGI, J.;
- ARNOTT, I. D. R.
Publication type:
Article
Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn's Disease: A Population-based Cohort Study.
Published in:
Journal of Crohn's & Colitis, 2020, v. 14, n. 9, p. 1241, doi. 10.1093/ecco-jcc/jjaa044
By:
- Jenkinson, P W;
- Plevris, N;
- Siakavellas, S;
- Lyons, M;
- Arnott, I D;
- Wilson, D;
- Watson, A J M;
- Jones, G-R;
- Lees, C W
Publication type:
Article
Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Published in:
Journal of Crohn's & Colitis, 2019, v. 13, n. 9, p. 1111, doi. 10.1093/ecco-jcc/jjz042
By:
- Plevris, N;
- Chuah, C S;
- Allen, R M;
- Arnott, I D;
- Brennan, P N;
- Chaudhary, S;
- Churchhouse, A M D;
- Din, S;
- Donoghue, E;
- Gaya, D R;
- Groome, M;
- Jafferbhoy, H M;
- Jenkinson, P W;
- Lam, W L;
- Lyons, M;
- Macdonald, J C;
- MacMaster, M;
- Mowat, C;
- Naismith, G D;
- Potts, L F
Publication type:
Article
Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis.
Published in:
American Journal of Gastroenterology (Springer Nature), 2009, v. 104, n. 3, p. 673, doi. 10.1038/ajg.2008.119
By:
- Ho, G. T.;
- Lee, H. M.;
- Brydon, G.;
- Ting, T.;
- Hare, N.;
- Drummond, H.;
- Shand, A. G.;
- Bartolo, D. C.;
- Wilson, R. G.;
- Dunlop, M. G.;
- Arnott, I. D.;
- Satsangi, J.
Publication type:
Article

Found: 24